Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291681 | 0.90 | LMNA (0.47) | LMNAKMT2AGABRA1GABRB2ADRB2 | |
| SCHEMBL3289057 | 0.89 | ADRB2 (0.43) | LMNAKMT2AGABRA1GABRB2ADRB2 | |
| SCHEMBL14019665 | 0.87 | TOP1 (0.38) | LMNAKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL3291390 | 0.86 | LMNA (0.39) | LMNAKMT2AGABRA1GABRB2ADRB2 | |
| SCHEMBL3294020 | 0.84 | LMNA (0.47) | LMNAKMT2AGABRA1GABRB2P2RX3 | |
| SCHEMBL3311165 | 0.83 | LMNA (0.42) | LMNAKMT2AGABRA1GABRB2P2RX3 | |
| SCHEMBL3288787 | 0.82 | DDB1 (0.41) | LMNAKMT2AGABRA1GABRB2ADRB2 | |
| SCHEMBL3296359 | 0.79 | LMNA (0.52) | LMNAKMT2AMEN1MAPTTHRB | |
| SCHEMBL3294927 | 0.79 | LMNA (0.52) | LMNAKMT2AGABRA1GABRA3MEN1 | |
| SCHEMBL14019651 | 0.79 | CNR2 (0.40) | LMNAGABRA1GABRB2POLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-7718621-B2 | Macrolones—amino substituted quinolones | GLAXO GROUP LTD. (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1951735-A1 | NEW 4*-SUBSTITUTED ERYTHROMYCIN DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-08-06 | — | — | EP | disclosed |
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| EP-1824870-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007054295-A1 | NEW 4*-SUBSTITUTED ERYTHROMYCIN DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054295-A1 | NEW 4*-SUBSTITUTED ERYTHROMYCIN DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090773-A1 | Macrolones - Amino Substituted Quinolones | MRPL21, Q6ZSR9, QARS1 | LMNA 1318/4885KMT2A 2845/4885GABRA1 3028/4885 |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | LMNA 1555/4885KMT2A 695/4885GABRA1 2319/4885 |
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | MRPL21, CYP3A4, CYP51A1 | LMNA 1751/4885KMT2A 2873/4885GABRA1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.